- Business
- Shandong Weigao Blood Purification Products Co., Ltd. is a China-based medical technology company primarily engaged in the research, development, manufacture, and distribution of medical devices, consumables, and solutions for blood purification and advanced pharmaceutical packaging. Founded in 2004 and headquartered in Weihai, Shandong Province, China, the company operates as a core subsidiary of WEGO Group (Weigao Holding) and serves public and private hospitals, specialized nephrology centers, hemodialysis clinics, and biopharmaceutical enterprises across China and overseas markets. The company provides a comprehensive ecosystem spanning both hemodialysis and peritoneal dialysis clinical pathways as well as specialized drug delivery systems. Its primary product lines include: Hemodialysis Consumables, comprising high-flux and low-flux polysulfone membrane dialyzers, hemodialysis bloodline tubing sets, arteriovenous fistula puncture needles, hemodialysis dry powder, liquid dialysis concentrates, and equipment disinfectant fluids; Dialysis Equipment and Systems, comprising single-pump and double-pump hemodialysis machines, hemodiafiltration systems, continuous renal replacement therapy (CRRT) machines, automated peritoneal dialysis (APD) cyclers, and reverse osmosis water treatment units produced through internal research and strategic manufacturing partnerships with international medical device leaders such as Nikkiso and Terumo; Peritoneal Dialysis Products, comprising peritoneal dialysis solutions in non-PVC dual-bag packaging, automated peritoneal dialysis fluid sets, catheter connection kits, and digital home dialysis management platforms; and Advanced Pharmaceutical Packaging and Drug Delivery Systems, comprising pre-filled syringe (PFS) systems, automatic safety injection devices, pre-sterilized glass and polymer barrels, rigid needle shields, plunger stoppers, and biopharmaceutical process filtration consumables. In recent corporate developments, the company completed its initial public offering on the Main Board of the Shanghai Stock Exchange under the ticker 603014 in May 2025, raising approximately RMB 1.09 billion to finance manufacturing capacity expansion, automated warehouse construction, and research center upgrades. Following its listing, the company executed a major corporate reorganization and asset acquisition in 2026, issuing shares valued at RMB 8.51 billion to acquire a 100% equity stake in Shandong Weigao Purui Medical Packaging Co., Ltd. This strategic transaction established a dual-pillar operational structure combining blood purification technologies with high-barrier pharmaceutical packaging and biopharmaceutical filtration, accelerating the company's product diversification, supply chain integration, and commercial expansion in upstream bioprocessing markets.